Featured Story

  • Merck prods cattle producers to help it test the safety of withdrawn Zilmax

    The Wall Street Journal said that the drugmaker plans to test Zilmax in about 250,000 cattle in a randomized, controlled study. But sources say beef producers like Cargill and JBS SA have pushed back against the move. While Merck planned to have the feed additive on the market by this summer, the study has been delayed.

Virbac H1 sales hurt by Iverhart recall in U.S.

Sales of products for the production animal category in emerging markets were up significantly for French drugmaker Virbac in the first half. It was helped in South America by the integration of Uruguay-based Santa Elena, which it bought last year, but it was not enough to overcome difficult foreign exchange rates and weak sales in the U.S. after having to recall 34 lots of its Iverhart Plus chewable heartworm medicine last year.

Seizures in horses in Kentucky focus attention on drug compounding

Former FDA associate commissioner Peter J. Pitts added his voice to calls for the need to regulate animal drug compounders who put together illegal animal drug combos, accusing the FDA of doing nothing while animals are dying from the practice.

Sanofi's Merial revives heartworm treatment

Spring ended with approval for a chewable treating ticks and fleas in May, followed by another edible drug in June for canine osteoarthritis. Now the market for dog meds is getting even bigger as Sanofi's Merial has just relaunched its heartworm tablet.

Why is there increased activity in animal health IPOs?

Husch Blackwell, a Kansas City, MO-based national legal firm with a Food & Agribusiness team, has laid out the top reasons behind the sudden rush--citing increased news coverage of the sector as one of them.

France's AB Science warned by FDA for its canine cancer drug promotion

With a slap to French animal health company AB Science, the FDA is sending out a poignant reminder that there are no exceptions to its rules when it comes to marketing medications. It issued the company a warning letter regarding its Kinavet-CA1 canine drug, intended for canine mast cell tumors, for allegedly boasting its off-label uses without approval.


From Our Sister Sites


Six biotechs were expected to go public this week, eyeing nearly $400 million combined, but that potential has so far amounted to one deeply discounted offering, one bottom-of-the-range debut and one outright cancelation.

FierceBiotech Research

Researchers at the University of Iowa have developed a vaccine that showed protection in mice against dust mite allergies.